19 December 2014
EMA/710373/2014
EMEA/H/C/2517

Public statement

Ipreziv

Withdrawal of the marketing authorisation in the European Union

On 27 October 2014, the European Commission withdrew the marketing authorisation for Ipreziv (azilsartan medoxomil) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Takeda Pharma A/S, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Ipreziv was granted marketing authorisation in the EU on 07 December 2011 for the treatment of essential hypertension in adults. It belongs to an established class of medicines in the treatment of hypertension. The product had not been marketed in the EU from the time of the marketing authorisation on 07 December 2011.

Ipreziv was a duplicate application to Edarbi, which is marketed in the EU. The marketing authorisation holder will maintain the marketing authorisation for Edarbi.

The European Public Assessment Report (EPAR) for Ipreziv will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact